Within its last year performance, MNKD fell by -7.15%, with highs and lows ranging from $7.07 to $3.38, whereas the simple moving average jumped by 25.38% in the last 200 days.
On November 24, 2025, Truist started tracking Mannkind Corp (NASDAQ: MNKD) recommending Buy. A report published by Leerink Partners on November 13, 2025, Initiated its previous ‘Outperform’ rating for MNKD. Wells Fargo also rated MNKD shares as ‘Overweight’, setting a target price of $10 on the company’s shares in an initiating report dated October 20, 2025. Leerink Partners Initiated an Outperform rating on October 10, 2025, and assigned a price target of $9. H.C. Wainwright initiated its ‘Buy’ rating for MNKD, as published in its report on July 16, 2025. Mizuho’s report from April 10, 2025 suggests a price prediction of $12 for MNKD shares, giving the stock a ‘Outperform’ rating. Wedbush also rated the stock as ‘Outperform’.
Analysis of Mannkind Corp (MNKD)
Further, the quarter-over-quarter increase in sales is 17.20%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Mannkind Corp’s future performance, with equity being one of the most critical indicators. Taking into account the quick ratio of the company, currently set at 3.04, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and MNKD is recording an average volume of 3.93M. On a monthly basis, the volatility of the stock is set at 3.22%, whereas on a weekly basis, it is put at 3.22%, with a gain of 2.75% over the past seven days. Furthermore, long-term investors anticipate a median target price of $9.61, showing growth from the present price of $5.97, which can serve as yet another indication of whether MNKD is worth investing in or should be passed over.
How Do You Analyze Mannkind Corp Shares?
Mannkind Corp (MNKD) is based in the USA and is one of the most prominent companies operating in the Biotechnology market. When comparing Mannkind Corp shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 63.31, there is a growth in quarterly earnings of -36.95%.
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.85%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 57.29% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
